Safety and Efficacy of BFH772 in Psoriasis Patients

A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis.

This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.

Inclusion Criteria:

• Stable mild to moderate plaque psoriasis (BSA involvement < 10% or PASI < 10
• Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthritis
• Diagnosed or history of psoriasis for at least 6 months prior to screening

Exclusion Criteria:

• Nonplaque forms of psoriasis
• Drug-induced psoriasis
• Current use of beta blockers
• Congestive heart failure (NYHA >III), QT interval >450msec or poorly controlled diabetes mellitus

Other protocol-defined inclusion/exclusion criteria may apply